vs
ADMA BIOLOGICS, INC.（ADMA）与HALOZYME THERAPEUTICS, INC.（HALO）财务数据对比。点击上方公司名可切换其他公司
HALOZYME THERAPEUTICS, INC.的季度营收约是ADMA BIOLOGICS, INC.的3.2倍（$451.8M vs $139.2M）。ADMA BIOLOGICS, INC.净利率更高（35.5% vs -31.3%，领先66.8%）。HALOZYME THERAPEUTICS, INC.同比增速更快（51.6% vs 18.4%）。HALOZYME THERAPEUTICS, INC.自由现金流更多（$217.6M vs $34.6M）。过去两年HALOZYME THERAPEUTICS, INC.的营收复合增速更高（51.9% vs 30.4%）
ADMA生物制剂公司是一家专注于研发、生产及商业化特种血浆来源免疫球蛋白疗法的生物制药企业，主要面向美国市场，为原发性免疫缺陷及其他免疫相关疾病患者、医护人员和医疗机构提供免疫健康领域的治疗方案。
Halozyme Therapeutics是一家美国生物技术企业，专注于肿瘤领域创新疗法研发，核心管线均针对肿瘤微环境进行靶向干预，致力于为全球癌症患者提供更安全高效的治疗选择。
ADMA vs HALO — 直观对比
营收规模更大
HALO
是对方的3.2倍
$139.2M
营收增速更快
HALO
高出33.2%
18.4%
净利率更高
ADMA
高出66.8%
-31.3%
自由现金流更多
HALO
多$183.0M
$34.6M
两年增速更快
HALO
近两年复合增速
30.4%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $139.2M | $451.8M |
| 净利润 | $49.4M | $-141.6M |
| 毛利率 | 63.8% | 82.6% |
| 营业利润率 | 45.1% | -20.6% |
| 净利率 | 35.5% | -31.3% |
| 营收同比 | 18.4% | 51.6% |
| 净利润同比 | -55.9% | -203.3% |
| 每股收益（稀释后） | $0.20 | $-1.13 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ADMAHALO
| Q4 25 | $139.2M | $451.8M | ||
| Q3 25 | $134.2M | $354.3M | ||
| Q2 25 | $122.0M | $325.7M | ||
| Q1 25 | $114.8M | $264.9M | ||
| Q4 24 | $117.5M | $298.0M | ||
| Q3 24 | $119.8M | $290.1M | ||
| Q2 24 | $107.2M | $231.4M | ||
| Q1 24 | $81.9M | $195.9M |
净利润ADMAHALO
| Q4 25 | $49.4M | $-141.6M | ||
| Q3 25 | $36.4M | $175.2M | ||
| Q2 25 | $34.2M | $165.2M | ||
| Q1 25 | $26.9M | $118.1M | ||
| Q4 24 | $111.9M | $137.0M | ||
| Q3 24 | $35.9M | $137.0M | ||
| Q2 24 | $32.1M | $93.2M | ||
| Q1 24 | $17.8M | $76.8M |
毛利率ADMAHALO
| Q4 25 | 63.8% | 82.6% | ||
| Q3 25 | 56.3% | 84.4% | ||
| Q2 25 | 55.1% | 85.8% | ||
| Q1 25 | 53.2% | 81.7% | ||
| Q4 24 | 53.9% | 85.9% | ||
| Q3 24 | 49.8% | 83.0% | ||
| Q2 24 | 53.6% | 82.9% | ||
| Q1 24 | 47.8% | 85.5% |
营业利润率ADMAHALO
| Q4 25 | 45.1% | -20.6% | ||
| Q3 25 | 38.0% | 61.5% | ||
| Q2 25 | 35.1% | 62.2% | ||
| Q1 25 | 30.4% | 53.4% | ||
| Q4 24 | 32.6% | 58.9% | ||
| Q3 24 | 33.1% | 56.3% | ||
| Q2 24 | 36.6% | 50.7% | ||
| Q1 24 | 26.7% | 48.8% |
净利率ADMAHALO
| Q4 25 | 35.5% | -31.3% | ||
| Q3 25 | 27.1% | 49.5% | ||
| Q2 25 | 28.1% | 50.7% | ||
| Q1 25 | 23.4% | 44.6% | ||
| Q4 24 | 95.2% | 46.0% | ||
| Q3 24 | 30.0% | 47.2% | ||
| Q2 24 | 29.9% | 40.3% | ||
| Q1 24 | 21.7% | 39.2% |
每股收益（稀释后）ADMAHALO
| Q4 25 | $0.20 | $-1.13 | ||
| Q3 25 | $0.15 | $1.43 | ||
| Q2 25 | $0.14 | $1.33 | ||
| Q1 25 | $0.11 | $0.93 | ||
| Q4 24 | $0.45 | $1.06 | ||
| Q3 24 | $0.15 | $1.05 | ||
| Q2 24 | $0.13 | $0.72 | ||
| Q1 24 | $0.08 | $0.60 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $87.6M | $133.8M |
| 总债务越低越好 | $72.1M | $2.1B |
| 股东权益账面价值 | $477.3M | $48.8M |
| 总资产 | $624.2M | $2.5B |
| 负债/权益比越低杠杆越低 | 0.15× | 43.89× |
8季度趋势，按日历期对齐
现金及短期投资ADMAHALO
| Q4 25 | $87.6M | $133.8M | ||
| Q3 25 | $61.4M | $419.7M | ||
| Q2 25 | $90.3M | $61.9M | ||
| Q1 25 | $71.6M | $176.3M | ||
| Q4 24 | $103.1M | $115.8M | ||
| Q3 24 | $86.7M | $154.3M | ||
| Q2 24 | $88.2M | $187.9M | ||
| Q1 24 | $45.3M | $164.6M |
总债务ADMAHALO
| Q4 25 | $72.1M | $2.1B | ||
| Q3 25 | $72.4M | $1.5B | ||
| Q2 25 | — | $1.5B | ||
| Q1 25 | — | $1.5B | ||
| Q4 24 | $72.3M | $1.5B | ||
| Q3 24 | — | $1.5B | ||
| Q2 24 | — | $1.5B | ||
| Q1 24 | — | $1.5B |
股东权益ADMAHALO
| Q4 25 | $477.3M | $48.8M | ||
| Q3 25 | $431.2M | $503.9M | ||
| Q2 25 | $398.3M | $332.7M | ||
| Q1 25 | $373.4M | $482.3M | ||
| Q4 24 | $349.0M | $363.8M | ||
| Q3 24 | $231.9M | $452.7M | ||
| Q2 24 | $188.3M | $289.4M | ||
| Q1 24 | $153.7M | $177.8M |
总资产ADMAHALO
| Q4 25 | $624.2M | $2.5B | ||
| Q3 25 | $568.7M | $2.2B | ||
| Q2 25 | $558.4M | $2.1B | ||
| Q1 25 | $510.6M | $2.2B | ||
| Q4 24 | $488.7M | $2.1B | ||
| Q3 24 | $390.6M | $2.1B | ||
| Q2 24 | $376.4M | $2.0B | ||
| Q1 24 | $350.9M | $1.8B |
负债/权益比ADMAHALO
| Q4 25 | 0.15× | 43.89× | ||
| Q3 25 | 0.17× | 3.00× | ||
| Q2 25 | — | 4.54× | ||
| Q1 25 | — | 3.13× | ||
| Q4 24 | 0.21× | 4.14× | ||
| Q3 24 | — | 3.32× | ||
| Q2 24 | — | 5.19× | ||
| Q1 24 | — | 8.44× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $35.6M | $219.0M |
| 自由现金流经营现金流 - 资本支出 | $34.6M | $217.6M |
| 自由现金流率自由现金流/营收 | 24.8% | 48.2% |
| 资本支出强度资本支出/营收 | 0.8% | 0.3% |
| 现金转化率经营现金流/净利润 | 0.72× | — |
| 过去12个月自由现金流最近4个季度 | $27.8M | $644.6M |
8季度趋势，按日历期对齐
经营现金流ADMAHALO
| Q4 25 | $35.6M | $219.0M | ||
| Q3 25 | $13.3M | $178.6M | ||
| Q2 25 | $21.1M | $99.7M | ||
| Q1 25 | $-19.7M | $154.2M | ||
| Q4 24 | $50.2M | $178.5M | ||
| Q3 24 | $25.0M | $115.4M | ||
| Q2 24 | $45.6M | $55.8M | ||
| Q1 24 | $-2.2M | $129.4M |
自由现金流ADMAHALO
| Q4 25 | $34.6M | $217.6M | ||
| Q3 25 | $-1.1M | $175.6M | ||
| Q2 25 | $18.7M | $98.1M | ||
| Q1 25 | $-24.4M | $153.3M | ||
| Q4 24 | $47.5M | $175.4M | ||
| Q3 24 | $24.0M | $113.9M | ||
| Q2 24 | $43.6M | $53.2M | ||
| Q1 24 | $-4.6M | $125.9M |
自由现金流率ADMAHALO
| Q4 25 | 24.8% | 48.2% | ||
| Q3 25 | -0.8% | 49.6% | ||
| Q2 25 | 15.3% | 30.1% | ||
| Q1 25 | -21.2% | 57.9% | ||
| Q4 24 | 40.4% | 58.9% | ||
| Q3 24 | 20.0% | 39.3% | ||
| Q2 24 | 40.7% | 23.0% | ||
| Q1 24 | -5.6% | 64.3% |
资本支出强度ADMAHALO
| Q4 25 | 0.8% | 0.3% | ||
| Q3 25 | 10.7% | 0.9% | ||
| Q2 25 | 2.0% | 0.5% | ||
| Q1 25 | 4.1% | 0.4% | ||
| Q4 24 | 2.3% | 1.0% | ||
| Q3 24 | 0.9% | 0.5% | ||
| Q2 24 | 1.9% | 1.1% | ||
| Q1 24 | 2.9% | 1.8% |
现金转化率ADMAHALO
| Q4 25 | 0.72× | — | ||
| Q3 25 | 0.36× | 1.02× | ||
| Q2 25 | 0.62× | 0.60× | ||
| Q1 25 | -0.73× | 1.31× | ||
| Q4 24 | 0.45× | 1.30× | ||
| Q3 24 | 0.70× | 0.84× | ||
| Q2 24 | 1.42× | 0.60× | ||
| Q1 24 | -0.12× | 1.68× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ADMA
暂无分部数据
HALO
| Royalty | $258.0M | 57% |
| Products | $122.7M | 27% |
| Proprietary Products Sales | $59.6M | 13% |
| Device Partnered Products | $12.9M | 3% |
